

Endothelial RANK signaling triggers bone marrow inflammaging through IL-1 β expression

Yasuhiro Kobayashi

`yasuhiro.kobayashi@mdu.ac.jp`

Matsumoto Dental University <https://orcid.org/0000-0002-0903-3226>

Rina Iwamoto

Matsumoto Dental University

Takumi Takahashi

Matsumoto Dental University

Masayoshi Ishida

Matsumoto Dental University

Zhifeng He

Matsumoto Dental University

Kohei Murakami

Okayama University of Science

Tomoyo Hara

University of Tokushima

Byambasuren Ganbaatar

University of Tokushima

Hiroki Yamagami

University of Tokushima

Itsuro Endo

University of Tokushima

Takahiro Iguchi

University of Tokyo

Toru Hiraga

Matsumoto Dental University

Toshihide Mizoguchi

Tokyo Dental College

Midori Nakamura

Matsumoto Dental University

Yutaro Ando

Showa University

Hisataka Yasuda

Tokyo Dental College

Masayuki Tsukasaki

Showa University

Kazuo Okamoto

Kanazawa University

Hiroshi Takayanagi

University of Tokyo

Nobuyuki Udagawa

Matsumoto Dental University

Research Article

Keywords: Senescence, Tnfrf11a, endothelial cell, inflammaging

Posted Date: September 3rd, 2026

DOI: <https://doi.org/10.21203/rs.3.rs-10899322/v1>

License:  This work is licensed under a Creative Commons Attribution 4.0 International License.

[Read Full License](#)

Additional Declarations: The authors declare no competing interests.

Abstract

Senescent cell accumulation in the bone marrow promotes inflammaging, hematopoietic stem cell dysfunction, and myeloid-biased hematopoiesis, contributing to the onset of age-related diseases. However, the mechanisms underlying the emergence of senescent cells in the bone marrow remain poorly understood. Here, we identify endothelial RANK signaling as a key regulator of bone marrow senescence. Young *Tnfrsf11b* (osteoprotegerin, OPG)-deficient mice exhibited premature accumulation of senescent cells and myeloid-biased hematopoiesis, phenocopying middle-aged wild-type mice. Endothelial-specific deletion of *Tnfrsf11a* (RANK), blockade of RANKL, and in vivo tracing with fluorescent-labelled RANKL revealed that RANK signaling in endothelial cells drives senescent cell accumulation in the bone marrow. Bulk and single-cell RNA sequencing, and IL-1 β neutralization demonstrate that RANK signaling induces IL-1 β expression in endothelial cells, which in turn promotes bone marrow inflammaging. These findings identify endothelial RANK as a critical initiator of bone marrow senescence, thereby driving inflammaging, a potential therapeutic target for age-related diseases.

Introduction

Aging is a major contributor to the onset and progression of various chronic diseases, including type II diabetes mellitus (DM), osteoporosis, sarcopenia^{1, 2}, particularly in individuals over middle age³. In this context, senescent cells have emerged as a potential therapeutic target for age-associated chronic conditions^{4, 5}. In vitro studies have demonstrated that cellular senescence can be triggered by DNA damage resulting from various stresses⁶⁻⁸. However, the upstream signals that initiate cellular senescence during physiological aging in vivo remain largely undefined.

Senescent cells are characterized by a permanent arrest of the cell cycle, yet they remain metabolically active and secrete a variety of pro-inflammatory cytokines and proteolytic enzymes collectively referred to as the senescence-associated secretory phenotype (SASP)⁷. Through this secretory profile, senescent cells contribute to a persistent, low-grade inflammatory state in tissues—a phenomenon termed “inflammaging”⁹. Accumulating evidence indicates that clearance of senescent cells can ameliorate age-associated organ dysfunction, including in bone tissue¹⁰ and various senolytic therapies are currently being evaluated in clinical trials¹¹. A central question in gerontology and age-related disease prevention is how senescent cells arise within tissues. However, the mechanisms underlying the emergence of senescent cells within the bone marrow remain largely unknown.

Receptor activator of NF- κ B ligand (RANKL, encoded by *Tnfrsf11*), its receptor RANK (encoded by *Tnfrsf11a*), and the decoy receptor osteoprotegerin (OPG, encoded by *Tnfrsf11b*) are known to play crucial roles not only in bone metabolism but also in the development of the immune system in the thymus, lymph nodes, gut, skin, and central nervous system¹². In addition, they are involved in mammary gland development, regulation of thermogenesis via the brain, and control of the hair cycle¹³. Beyond

their physiological functions, RANKL-RANK-OPG signaling has also been implicated in various pathological conditions, including breast cancer progression and metastasis, type 2 DM, and sarcopenia^{12, 13}. Interestingly, young OPG-deficient (OPG KO) mice exhibit several phenotypes that resemble those observed in aged animals, such as increased bone marrow adiposity, impaired spermatogenesis, vascular calcification, premature growth plate closure, and severe osteopenia. These findings suggest that excessive or unregulated RANKL-RANK signaling may contribute to the acceleration of aging-related changes. However, the precise mechanisms by which RANKL-RANK signaling promotes aging remain to be elucidated.

It has been proposed that continuous low-grade IL-1 signals contribute to the impairment of hematopoietic stem cell function, and then act as a driver of clonal hematopoiesis of indeterminate potential and myeloproliferative and myelodysplastic neoplasm¹⁴. Moreover, IL-1 secreted from bone marrow stromal cells (BMSCs) and macrophages exacerbates hematopoietic aging and platelet-biased hematopoiesis, respectively, in aged mice^{15, 16}. Thus, IL-1 signals are largely involved in hematopoietic disorders in aged human and mice. However, which cells express IL-1, and which cells receive IL-1 in middle-aged bone marrow are not fully understood.

Here, we found that treatment of OPG KO mice with anti-RANKL antibodies rescued age-associated bone phenotypes, including senescent cell accumulation and myeloid-biased hematopoiesis. Fluorescent-labeled RANKL tracing and genetic studies revealed that RANKL-RANK signaling in endothelial cells upregulates IL-1 β expression in the bone marrow, thereby inducing cellular senescence in BMSCs and driving myeloid-biased hematopoiesis. Together, these findings identify endothelial RANK signaling as a potential therapeutic target for preventing bone marrow inflammaging.

Results

OPG deficiency accelerates age-associated phenotypes in bone marrow

Both young (8-week-old) and middle-aged (32-week-old) OPG KO exhibited lower bone mass with higher bone marrow adiposity, mirroring characteristics commonly observed in middle-aged and elderly humans (Extended Data Fig. 1a, b) as shown previously¹⁷. This prompted us to investigate additional age-associated phenotypes such as the accumulation of senescent cells, myeloid-biased hematopoiesis, and inflammaging^{18, 19}, in OPG KO mice. SPiDER- β -gal (fluorescent substrate for senescence-associated- β -galactosidase)-positive senescent cells were increased in young and middle-aged OPG KO as well as middle-aged wild-type mice (Fig. 1a) associated with the significant decreasing Ki67-positive proliferative cells and the increased perilipin-positive adipocytes and CD41a-positive megakaryocytes (Extended Data Fig. 1b-d), as previously shown in aged bone marrow²⁰. Consistent with the myeloid-biased hematopoiesis observed in aged humans and mice^{21, 22}, young OPG KO mice exhibited increased neutrophil and reduced lymphocyte frequencies, a phenotype also observed in middle-aged WT and OPG

KO mice (Fig. 1b). These findings suggest that myeloid-biased hematopoiesis is already established in young OPG KO mice. Furthermore, qRT-PCR analysis revealed upregulation of senescence markers such as *p16* and *p21* and SASP-related genes in bone tissues of OPG KO mice (Fig. 1c).

We next investigated whether the neutralization of RANKL rescues age-related phenotypes in OPG KO mice by the administration of anti-mouse RANKL antibody (anti-RANKL Ab). Anti-RANKL Ab rescued the increased number of SPiDER- β -gal-positive senescent cells, and myeloid-biased hematopoiesis observed in OPG KO mice as well as the decreased bone mass (Fig. 1d-f). Anti-RANKL Ab also decreased the expression of *p16* and *p21* mRNA, increased Ki67-positive cells, and decreased megakaryocytes, but not adipocyte number, in the bone marrow from OPG KO mice (Extended Data Fig. 1e-h).

Endothelial cells are targets of RANKL in middle-aged bone marrow

To determine the RANK-expressing cells in middle-aged bone marrow, fluorescent-labeled recombinant RANKL (Fluor555-rRANKL) was intravenously injected into young and middle-aged mice. Fluor555-rRANKL-positive signals were observed in CD31- or Endomucin (Emcn)-positive endothelial cells from middle-aged bone marrow, but not in young mice (Fig. 2a). Flow cytometric analysis confirmed that Fluor555-rRANKL signals were markedly detected in endothelial cells, but not in BMSC-enriched or CD45-positive immune cell fraction (Fig. 2b).

Immunofluorescence analyses using VE-cadherin (Cdh5)-Cre; tdTomato (VE-cadherin-tom) and RANK-Cre; tdTomato (RANK-tom) reporter mice demonstrated increased numbers and frequencies of VE-cadherin/RANK double-positive cells in middle-aged bone marrow, as well as those of RANK-tom-positive CD31⁺Emcn⁺ endothelial cells (Fig. 2c,d). In contrast, RANK-tom-positive cells lacked expression of the leptin receptor (*Lepr*) and the macrophage marker F4/80 around the bone marrow sinusoid (Extended Data Fig. 2a). Moreover, RANKL-positive areas, including both cellular and extracellular matrix-associated signals, were significantly increased in middle-aged bone marrow (Extended Data Fig. 2b).

Endothelial RANK accelerates age-associated phenotypes in bone

To investigate the role of endothelial RANK signaling in age-related bone phenotypes, we generated endothelial cell-specific RANK-deficient mice (VE-Cadherin-Cre; *RANK*^{*fl/fl*}; EC-RANK cKO). Intravenous fluor555-rRANKL injection confirmed reduced RANK expression in endothelial cells (Extended Data Fig. 3a). μ CT analysis showed significantly increased trabecular bone volume, thickness, and number in middle-aged EC-RANK cKO mice versus WTs (Fig. 3a). Histomorphometry revealed increased osteoblast number, osterix-positive osteoblasts, and bone formation rate, while osteoclast number was unchanged (Extended Data Fig. 3b–e), indicating preserved bone mass through enhanced bone formation. Histological and FACS analyses showed fewer p16- and SPiDER- β -gal-positive senescent cells in EC-RANK cKO mice (Fig. 3b, Extended Data Fig. 4a,b). In addition, myeloid-biased hematopoiesis, reduced Ki67-positive cells, increased megakaryocytes, and elevated SASP factors (*Il1b*, *Tnfa*) were rescued

(Fig. 3c, Extended Data Fig. 4c–e), suggesting that endothelial RANK signaling drives age-associated bone phenotypes.

Impaired hematopoietic recovery has been reported in aged mice after myeloablative 5-fluorouracil (FU) treatment, which also induces fatty marrow formation^{15,23}. We therefore examined hematopoietic recovery in middle-aged EC-RANK cKO mice. Histology showed reduced bone marrow cellularity in all groups at day 7 after 5-FU treatment, followed by recovery by day 14 (Extended Data Fig. 4f). Although marrow cellularity during recovery was similar among groups, myeloid-biased hematopoiesis was rescued in middle-aged EC-RANK cKO mice, but not in middle-aged WTs (Fig. 3d,e). These findings suggest that age-associated myeloid-biased hematopoiesis is partly driven by alterations in the bone marrow microenvironment, including endothelial, stromal, and hematopoietic cells.

Bone regenerative capacity declines with age²⁴. μ CT analysis demonstrated that newly formed trabecular bone volume was significantly increased in middle-aged EC-RANK cKO mice (Fig. 3f). Consistently, histological analysis revealed a greater abundance of osterix-positive osteoblasts along newly formed bone surfaces in these mice (Fig. 3g).

RANK signaling induces inflammaging through IL-1 β

We next performed RNA-seq analysis to identify secreted factors mediating bone marrow senescence downstream of endothelial RANK signaling (Fig. 4a–f). The top 30 genes upregulated in the femora of middle-aged controls (Mcont) relative to young controls (Ycont) predominantly reflected immune and inflammatory responses, proteolysis and cell adhesion, whereas the top 30 downregulated genes were mainly involved in development and bone formation (Fig. 4a). Comparison with middle-aged EC-RANK cKO mice (McKO) identified 8 downregulated and 3 upregulated genes (Fig. 4b). Among genes elevated in Mcont but reduced in McKO, *Il1b* emerged as a candidate driver of bone marrow senescence, whereas *Col14a1* may act suppressively (Fig. 4c,d).

To validate this, we reanalyzed a public bone marrow scRNA-seq dataset (GSE145477)²⁵. UMAP analysis identified four clusters, including a CD31- or *Emcn*-positive endothelial cluster (Extended Data Fig. 5a). Differential expression and gene ontology analyses revealed enrichment of IL-1 β regulatory pathways in RANK-positive endothelial cells, suggesting that RANK signaling promotes *Il1b* expression (Fig. 4e). Consistently, endothelial cells from middle-aged mice expressed higher *Il1b* levels than those from young mice (Fig. 4f, Extended Data Fig. 5b,c).

Immunofluorescence analysis further showed strong IL-1 β signals in VE-cadherin-tom-positive endothelial cells and neighboring cells in middle-aged bone marrow, which were markedly reduced in EC-RANK cKO mice (Fig. 4g,h). Notably, CD31- and *Emcn*-positive endothelial cells lacked SPiDER- β -gal activity even in aged bone marrow (Extended Data Fig. 5d), indicating resistance to senescence. In vitro, rRANKL induced *Il1b* expression in RANK-overexpressing HUVECs, but not in bone marrow macrophages

(Extended Data Fig. 5e,f). Together, these findings indicate that endothelial RANK signaling promotes IL-1 β production and bone marrow inflammaging in middle-aged mice.

Neutralization of IL-1 β ameliorates age-associated phenotypes in bone marrow

To identify target cells of endothelial-derived IL-1 β , we reanalyzed public scRNA-seq data from young (1.5-month-old; M1.5) and aged (16-month-old; M16) mice (GSE145477)²⁵. UMAP visualization and violin plots showed high *Il1r1* expression in the *Cxcl12*⁺*Lepr*⁺ BMSC cluster in aged bone marrow (Fig. 5a,b; Extended Data Fig. 6a,b). DEG analysis revealed reduced osteoblast-related genes, including *Bglap* and *Col1a1*, in *Il1r1*-positive BMSCs (Extended Data Fig. 6c), suggesting that IL-1 β –IL1R1 signaling impairs osteogenic differentiation. Consistently, IL-1 β suppressed BMP2-induced alkaline phosphatase activity in ST2 cells (Extended Data Fig. 6d). scRNA-seq analysis further showed increased oxidative stress-response genes, including *Nfe2l2* and *Txnrd1*, in *Il1r1*-positive BMSCs (Extended Data Fig. 6e).

We therefore examined whether IL-1 β induces senescence through oxidative stress. IL-1 β increased γ H2AX foci, ROS production, mitochondrial dysfunction, and *Ifnb* expression in ST2 cells, together with senescence markers including SA- β -gal, p16, and p21 (Fig. 5c,d; Extended Data Fig. 6f–i). These findings suggest that IL-1R signaling promotes mitochondrial dysfunction, ROS production, and cellular senescence in BMSCs.

To define the role of IL-1 β in age-associated skeletal phenotypes, middle-aged mice were treated with anti-IL-1 β antibodies. Neutralization of IL-1 β reduced SPiDER- β -gal-positive BMSCs, rescued myeloid-biased hematopoiesis, and improved bone regeneration with increased *Osx*-positive osteoblasts (Fig. 5e–h). Together, these results demonstrate that IL-1 β drives age-associated bone phenotypes, including BMSC senescence, myeloid-biased hematopoiesis, and impaired bone regeneration.

Effects of RANKL Ab on bone marrow senescence in mice and humans

Finally, we investigated whether pharmacological blockade of RANKL could alleviate bone marrow aging. Anti-RANKL Ab treatment reduced the abundance of SPiDER- β -gal-positive senescent cells and rescued myeloid-biased hematopoiesis in middle-aged WT mice (Fig. 6a,b), supporting a central role for endothelial RANK signaling in age-associated bone marrow dysfunction.

Furthermore, GSEA of bulk RNA-seq data from iliac crest bone biopsies of postmenopausal women treated with placebo or denosumab (GSE141610)²⁶ revealed significant enrichment of the IL-1 response and inflammatory response gene sets in placebo-treated samples relative to denosumab-treated samples (Fig. 6c). The SenMayo gene signature also showed a trend toward enrichment in placebo-treated samples, although this did not reach statistical significance. These findings suggest that

denosumab attenuates inflammatory and senescence-associated transcriptional programs in human bone.

Collectively, our findings support a model in which age-associated activation of endothelial RANK signaling drives skeletal inflammaging through IL-1 β -dependent accumulation of senescent cells and myeloid-biased hematopoiesis in the aged bone marrow (Fig. 6e).

Discussion

We demonstrate that increased RANK signaling in endothelial cells in the bone marrow of middle-aged mice drives bone inflammaging, which in turn induces myeloid-biased hematopoiesis and bone regeneration following myeloablation and bone marrow ablation, respectively. Our comprehensive analyses, including scRNA-seq and RNA-seq, revealed that RANKL-RANK signaling induces IL-1 β expression in endothelial cells, and that IL-1 β subsequently promotes cellular senescence in bone marrow cells including BMSCs. Furthermore, treatment with a RANKL antibody or an IL-1 β antibody markedly ameliorates age-associated phenotypes in the bone marrow. Therefore, endothelial RANK signaling represents a potential therapeutic target for preventing the onset of bone marrow senescence.

Blood vessels, particularly Emcn^{high} CD31^{high} endothelial cells, have been shown to play important roles in bone development and hematopoiesis during aging^{27, 28}. However, the mechanisms by which endothelial cells regulate bone mass and hematopoiesis remain incompletely understood. Recently, we demonstrated that endothelial RANK plays a critical role in recruiting monocyte-macrophage lineage cells, including osteoclast precursors, from the bloodstream into the bone marrow microenvironment in ovariectomy (OVX)-induced osteoporosis²⁹. Blockade of endothelial RANKL-RANK signaling ameliorated OVX-induced bone loss without affecting bone mass under physiological conditions. In the present study, we further demonstrate a role for endothelial RANK in driving bone inflammaging in middle-aged mice. We found that both the number and proportion of RANK-expressing endothelial cells, as well as the area occupied by RANKL-expressing cells, were increased in middle-aged bone marrow. These findings strongly suggest that endothelial RANK signaling substantially contributes to aging-associated phenotypes, including myeloid-biased hematopoiesis and impaired bone regeneration in middle-aged bone marrow.

The present study provides evidence that OPG protects bone and suppresses inflammaging in bone. Previous studies have reported that circulating OPG levels increase with age in both men and women^{30,31}. However, these studies also demonstrated decreased bone mineral density and increased bone resorption markers, indicating that bone resorption is not primarily regulated by circulating OPG levels. Indeed, deletion of OPG in osteoblastic cells causes severe osteopenia without affecting serum OPG levels, further suggesting that local rather than systemic OPG is critical for bone homeostasis³². Therefore, serum OPG levels do not correlate with bone mass in either humans or mice. Taken together with our findings, these results suggest that age-associated increases in circulating OPG may

preferentially act on vascular endothelial cells to suppress RANK signaling and subsequent inflammatory aging in the bone marrow.

Nearly half of endothelial cells express RANK in the middle-aged bone marrow, as shown in VE-cadherin^{tom} and RANK^{tom} reporter mice. Notably, genes associated with IL-1 β production were enriched in these RANK-positive endothelial cells. These findings suggest that a subset of endothelial cells begins to express RANK and subsequently upregulates IL-1 β in response to RANKL stimulation. The molecular mechanisms underlying the increased number of RANK-expressing endothelial cells in middle-aged bone marrow remain unclear. A mouse brain capillary endothelial cell line, MBEC4, reportedly expresses *Csf1r*³³. *Csf1r* signaling induces RANK expression in osteoclast-lineage cells³⁴, and *Wnt5a-Ror2* signaling also promotes RANK expression in these cells³⁵. These studies raise the possibility that *Csf1r* and *Ror2* pathways could similarly promote RANK expression in endothelial cells. However, in our dataset, the expression levels of *Csf1r* and *Ror2* were negligible in endothelial cell clusters (unpublished data), suggesting that these pathways are unlikely to contribute to RANK expression in middle-aged bone marrow endothelial cells. Further studies are required to clarify the mechanisms by which RANK expression becomes elevated in a subset of vascular endothelial cells during aging.

Our study proposes that IL-1 β secreted from endothelial cells functions as an initiator of bone marrow inflammaging. IL-1 β has been reported to induce cytosolic leakage of mitochondrial DNA (mtDNA) through NF- κ B activation, thereby activating the cGAS-STING pathway and promoting the expression of SASP factors, including *Ifnb*³⁶. In the present study, IL-1 β treatment decreased mitochondrial membrane potential and induced *Ifnb* expression in ST2 cells. These findings indicate that IL-1 β can drive SASP expression in cells that respond to IL-1 receptor signaling.

Our scRNA-seq reanalysis revealed that BMSCs express high levels of *Il1r1* mRNA, encoding the IL-1 β receptor. Consistent with this observation, IL-1 β induced ROS production, increased the DNA-damage marker γ H2AX foci, and cellular senescence in stromal cell cultures, suggesting that ROS production probably damages DNA. Notably, treatment with anti-IL-1 β antibodies markedly reduced SA- β -gal-positive senescent cells and partially rescued myeloid-biased hematopoiesis in middle-aged mice. Thus, IL-1 β represents a therapeutic target for preventing the expansion of cellular senescence in middle-aged bone marrow.

NF- κ B is well known as an inducer of IL-1 β expression and as a key transcription factor activated downstream of IL-1 signaling^{37, 38}. RANKL-RANK signaling also activates NF- κ B to drive various biological processes, including osteoclastogenesis³⁹. Notably, RANKL treatment has been reported to induce *Il1b* mRNA and protein expression in rat neonatal cardiomyocytes⁴⁰. Based on these previous findings, it is highly plausible that RANK signaling activates NF- κ B and subsequently induces IL-1 β expression in endothelial cells. Consistent with this hypothesis, treatment with RANKL increased *Il1b* mRNA expression in human vascular endothelial cells after ectopic expression of RANK. Furthermore, our analyses showed that the number of RANKL-positive cells is also increased in middle-aged bone marrow.

This study has several limitations. First, the relatively small sample size limited the statistical power to evaluate the effects of denosumab on inflammatory conditions in human samples. Second, we cannot exclude the possibility that the anti-inflammatory effects of denosumab in human samples are mediated, at least in part, through mechanisms independent of senescent cells. Third, we also cannot rule out the possibility that the suppression of inflammaging by RANKL blockade or IL-1 β neutralization is attributable, at least in part, to indirect effects on other cell types or signaling pathways. Further clinical studies are warranted to determine whether denosumab or the IL-1 receptor antagonist anakinra reduces circulating levels of SASP factors in patients.

In summary, this study showed that bone marrow inflammaging may originate from enhanced RANK signaling in endothelial cells, which in turn promotes IL-1 β expression. Endothelial-derived IL-1 β then acts on bone marrow cells, including BMSCs, potentially establishing a vicious cycle of IL-1 β production that exacerbates inflammaging in middle-aged bone marrow.

Methods

Experimental animals

OPG KO mice on a C57BL/6 background were purchased from CLEA Japan (Tokyo, Japan) as originally described (Mizuno et al., 1998)⁴². RANK-Cre mice were generated and maintained as previously described (Maeda et al., 2012)³⁵. VE-cadherin-Cre (Kogata et al., 2006)⁴³ and RANK-flox mice (Powell et al., 2015)⁴⁴, as well as Rosa26-tdTomato mice (Madisen et al., 2010)⁴⁵, were obtained from the Jackson Laboratory. VE-cadherin-Cre mice were crossed with RANK^{fl/fl} mice to generate EC-RANK cKO. VE-cadherin-Cre and RANK-Cre mice were crossed with Rosa26-tdTomato to generate lineage-tracing models. Unless otherwise stated, experiments were performed using male mice. For the bone marrow ablation experiments, female mice were used. The age of mice used in each experiment is indicated in the corresponding figure legends. All animals were maintained under specific pathogen-free (SPF) conditions at 24 $\pm$ 2 °C with 50–60% humidity under a 12-h light/dark cycle, with ad libitum access to sterilized water and chow. All animal experiments were approved by the Animal Management Committee of Matsumoto Dental University.

In vivo antibody and drug treatments

For RANKL neutralization, 8-week-old OPG KO mice or 32-week-old WT mice were injected subcutaneously with the neutralizing anti-RANKL monoclonal antibody OYC1 (Oriental Yeast; 5 mg/kg) or the non-neutralizing anti-RANKL control antibody OYC2 (Oriental Yeast; 5 mg/kg). Mice were euthanized 14 days after treatment⁴⁶.

For IL-1 β neutralization, 32-week-old WT mice received six intravenous injections over 2 weeks of anti-IL-1 β antibody (BE0246; InVivoMAb) or hamster control IgG (BE0260; InVivoMAb). For 5-fluorouracil (5-FU, 157027; Kyowa Kirin), 32-week-old control (RANK^{fl/fl}) and EC-RANK cKO mice, were injected

intravenously with 5-FU (250 mg/kg) or saline. Survival was monitored for 20 days, and mice were euthanized at the endpoint^{15, 23}.

Microcomputed tomography (μ CT)

Femora were harvested, soft tissues removed, and samples fixed in 4% paraformaldehyde (PFA, 162-16065; FUJIFILM). High-resolution μ CT was performed using a ScanXmate-A080 system (Comscantecno). Images were reconstructed and trabecular bone parameters, including bone volume fraction (BV/TV), trabecular number (Tb.N), trabecular thickness (Tb.Th) and trabecular separation (Tb.Sp), were quantified using TRI/3D-BON software (Ratoc). Scanning conditions were 29 kV and 250 μ A. A 1 mm region of the metaphyseal secondary spongiosa beginning 500 μ m distal to the growth plate was analyzed⁴⁷.

Histology and immunofluorescence

For routine histological and immunofluorescence analyses, femora were fixed in 4% PFA at 4 °C overnight, followed by decalcification in 20% EDTA (041-22031; FUJIFILM) at 4 °C for 3 days. For p16 immunostaining, unfixed and undecalcified femora were used to preserve antigenicity. After the respective pretreatments, samples were cryoprotected in 20 % sucrose in PBS at 4 °C overnight, embedded in O.C.T. compound, and sectioned at 10–20 μ m thickness using Kawamoto's film method with Cryofilm type IIIC (Section-Lab) and a tungsten carbide knife. Sections were blocked and incubated with primary antibodies overnight at 4 °C, followed by incubation with appropriate secondary antibodies for 1 h at room temperature. Primary antibodies used included RANK/Tnfrsf11a (clone AF692; R&D Systems; 1:50), CD31/PECAM-1 Alexa Fluor 488 (clone FAB3628G; R&D Systems; 1:100), Endomucin (clone sc-65495; Santa Cruz Biotechnology; 1:50), Perilipin (clone D1D8; Cell Signaling Technology; 1:200), RANKL (rat polyclonal, sc-7628; Santa Cruz Biotechnology; 1:50), CDKN2A/p16^{INK4a} (clone EPR20418; Abcam; 1:50), F4/80 FITC (clone Cl:A3-1; Abcam; 1:50), IL-1 β (rabbit polyclonal, P420B; Invitrogen; 1:100), Ki67 FITC (clone SolA15; eBioscience; 1:100), Ly6G FITC (clone S19018G; BioLegend; 1:100), CD3 Alexa Fluor 488 (clone 17A2; BioLegend; 1:100), CD45R/B220 PE (clone RA3-682; BioLegend; 1:100), and anti-Sp7/Osterix (rabbit polyclonal, ab22552; Abcam; 1:200), LepR (goat polyclonal, AF497; R&D Systems; 1:100). Secondary antibodies included FITC-conjugated donkey anti-rat IgG (clone AP189F; Sigma-Aldrich; 1:200), Alexa Fluor 488 donkey anti-rabbit IgG (ab150073; Abcam; 1:500), Alexa Fluor 488 donkey anti-sheep IgG (ab150177; Abcam; 1:500), Alexa Fluor 594 donkey anti-rabbit IgG (A21207; Invitrogen; 1:500), and Alexa Fluor 594 donkey anti-rat IgG (A21209; Invitrogen; 1:500). Control antibodies included purified rat IgG2b (clone 400601; BioLegend), normal rabbit IgG (148-09551; FUJIFILM), and sheep IgG (5-001-A; R&D Systems). Can Get Signal (NKB-601; TOYOKO) was used to enhance immunoreactions. Nuclei were counterstained with TO-PRO-3 iodide (T3605; Invitrogen). Senescence-associated β -galactosidase (SA- β -gal) activity was assessed using the SPiDER- β -gal (SG02; Dojindo) and SPiDER Blue (SG07; Dojindo) according to the manufacturer's instructions. Fluorescence images were acquired using a confocal laser scanning microscope (LSM 510; Carl Zeiss). For dynamic histomorphometric analyses, mice were injected intraperitoneally with calcein (Sigma-Aldrich; 20 mg/kg)

twice at 72-h intervals, and femora were collected 24-h after the final injection. Samples were embedded in methyl methacrylate (MMA), sectioned at 5 μ m thickness (SP1600; Leica), and mineral apposition rate (MAR), mineralizing surface per bone surface (MS/BS), and bone formation rate (BFR) were calculated⁴⁸. MMA sections were stained with toluidine blue or TRAP/ALP (294-67001; Wako) for osteoblast and osteoclast quantification⁴⁹.

RANK⁺ cell detection by Fluor555-rRANKL

Recombinant GST-RANKL (47187000; Oriental Yeast) was conjugated with HiLyte Fluor 555 using the HiLyte Fluor 555 Labeling Kit (LK14; Dojindo) according to the manufacturer's instructions⁴⁹. Mice were injected intravenously with 0.7 mg/kg Fluor 555-rRANKL. 1 h later, mice were perfusion-fixed with 4% PFA, femora collected, decalcified in 10% EDTA for 1 week, cryoprotected in 20% sucrose, and embedded in O.C.T. for sectioning (10 or 16 μ m).

Flow cytometry and cell sorting

Bone marrow cells were flushed from femora and tibiae with complete medium (α -MEM supplemented with 10% fetal bovine serum and L-glutamine). The cell suspension was enzymatically digested with Dispase II (Oenon; 2 μ g/mL), collagenase (FUJIFILM; 1 μ g/mL), and DNase I (Worthington; 10 μ g/mL) at 37 °C for 30 min with gentle agitation. Cell suspensions were filtered and subjected to red blood cell lysis using RBC lysis buffer (00-4333-57; eBioscience). Cells were washed and stained with fluorochrome-conjugated antibodies against CD31/PECAM1 Alexa Fluor 488 (clone FAB3628G; R&D Systems; 1:25), CD45 APC (clone 30-F11; BioLegend; 1:100), Ly6G FITC (clone S19018G; BioLegend; 1:200), CD11b Alexa Fluor 488 (clone M1/70; BioLegend; 1:100), CD3 Alexa Fluor 488 (clone 17A2; BioLegend; 1:100), and mouse/human B220 PE (clone RA3-6B2; BioLegend; 1:100), mouse Ter119 APC (clone TER-119; BioLegend; 1:100). Senescence-associated β -galactosidase activity was detected by addition of SPiDER- β -gal reagent (Dojindo; 1:1000) before analysis. After red blood cell lysis, bone marrow cells were incubated with CD45 MicroBeads (130-052-301; Miltenyi Biotec) for magnetic separation. CD45⁺ and CD45⁻ fractions were isolated using the MACS system, including a MACS MultiStand (130-042-303), MidiMACS Separator (130-042-302), and LS Columns (130-042-401) (Miltenyi Biotec). The CD45⁻ fraction was subsequently stained with fluorochrome-conjugated antibodies against mouse/rat CD31/PECAM1 Alexa Fluor 488 (clone FAB3628G; R&D Systems; 1:25), mouse CD45 APC (clone 30-F11; BioLegend; 1:100), and mouse Ter119 APC (clone TER-119; BioLegend; 1:100) and used for flow cytometric cell sorting. Cell populations were defined as CD31⁺CD45⁻Ter119⁻ or CD31⁻CD45⁻Ter119⁻ based on surface marker expression. Flow cytometry analysis was performed using an FC500 (Beckman Coulter). Flow cytometric cell sorting was performed using an FACS Aria IIu (BD Biosciences). Data were analyzed using FlowJo software (BD Biosciences).

Quantitative real-time PCR

Tibiae were homogenized in TRIzol (Thermo Fisher) using a TissueLyser II (Qiagen). Total RNA was isolated using the NucleoSpin RNA kit (Macherey-Nagel), and cDNA synthesized using ReverTra Ace

(TOYOBO). For endothelial and BMSC samples requiring preamplification, cDNA was generated using the iScript gDNA Clear cDNA Kit (Bio-Rad) followed by SsoAdvanced PreAmp Supermix. qPCR was performed using Fast SYBR Green Master Mix (Thermo Fisher) on a StepOnePlus system under standard cycling conditions. Relative expression was normalized to *Actb* (*ACTB*). Primer sequences are listed below.

Actb (mouse), 5'-CATCCGTAAAGACCTC-3' (forward) and

5'-ATGGAGCCACCGATCCACA-3' (reverse);

Cdkn1a (*p21*) (mouse), 5'-GCAGATCCACAGCGATATCCA-3' (forward)

and 5'-AACAGGTCGGACATCACCAG-3' (reverse);

Cdkn2a (*p16*) (mouse), 5'-TCTTTGTGTACCGCTGGGAAC-3' (forward)

and 5'-GCATCGCTAGAAGTGAAGCTAAGAA-3' (reverse);

Il1a (mouse), 5'-AGGGAGTCAACTCATTGGCG-3' (forward)

and 5'-TGGCAGAACTGTAGTCTTCGT-3' (reverse);

Il1b (mouse), 5'-GCAACTGTTCCTGAACTCAACT-3' (forward)

and 5'-ATCTTTTGGGGTCCGTCAACT-3' (reverse);

Il6 (mouse), 5'-CCACTTCACAAGTCGGAGGCTTA-3' (forward)

and 5'-TGCAAGTGCATCATCGTTGTTC-3' (reverse);

Tnfa (mouse), 5'-CTGTAGCCACGTCGTAGC-3' (forward)

and 5'-TTGAGATCCATGCCGTTG-3' (reverse).

Ccl2 (mouse), 5'-GCTACAAGAGGATCACCAGCAG-3' (forward)

and 5'-GTCTGGACCCATTCTTCTTGG-3' (reverse).

Cxcl1 (mouse), 5'-ACCGAAGTCATAGCCACACTC-3' (forward)

and 5'-CTCCGTTACTTGGGGACACC-3' (reverse);

Ifnb (mouse): 5'-GCCTTTGCCATCCAAGAGATGC-3' (forward)

and 5'-ACACTGTCTGCTGGTGGA-3' (reverse).

ACTB (human), 5'-CCAACCGCGAGAAGATGA-3' (forward)

and 5'-CCAGAGGCGTACAGGGATAG-3' (reverse);

IL1A (human), 5'-CGCCAATGACTCAGAGGAAGA-3' (forward)

and 5'-AGGGCGTCATTCAGGATGAA-3' (reverse);

IL1B (human), 5'-AGATGATAAGCCCACTCTACAG-3' (forward)

and 5'-ACATTCAGCACAGGACTCTC-3' (reverse);

IL6 (human), 5'-CAGGAGAAGATTCCAAAGAT-3' (forward)

and 5'-CTCTTGTTACATGTCTCCTT-3' (reverse);

TNF (human), 5'-CCCGAGTGACAAGCCTGTAG-3' (forward)

and 5'-GATGGCAGAGAGGAGGTTGAC-3' (reverse).

CCL2 (human), 5'-CAGCCAGATGCAATCAATGCC-3' (forward)

and 5'-TGGAATCCTGAACCCACTTCT-3' (reverse);

CXCL1 (human), 5'-AGGCAGGGGAATGTATGTGC-3' (forward)

and 5'-AGCCCCTTTGTTCTAAGCCA-3' (reverse);

Bone marrow ablation model

Performed as described by Matsushita et al. (2020)⁵⁰. In 32-week-old female control and EC-RANK cKO mice, the knee joint was exposed and a 26G needle used to access the intercondylar space. Bone marrow was removed stepwise using K-files (#35-50). The cavity was irrigated with saline and the incision sutured.

Bulk RNA-sequencing

Total RNA was extracted from mouse femurs as described above. RNA concentration and integrity were assessed using a NanoDrop ONE spectrophotometer (Thermo Fisher Scientific) and an Agilent TapeStation 4200 with the High Sensitivity RNA ScreenTape assay. For each sample, 100 ng of total RNA was subjected to rRNA depletion using the NEBNext rRNA Depletion Kit v2 (E7400; New England Biolabs), followed by library construction with the NEBNext Ultra II Directional RNA Library Prep Kit for Illumina (E7760; New England Biolabs). Indexed libraries were quantified using a Qubit Fluorometer and evaluated on a TapeStation D1000 ScreenTape assay. Sequencing was performed on an Illumina NovaSeq 6000 platform using the S1 Reagent Kit v1.5, generating paired-end 50-bp reads. Raw BCL files were converted to FASTQ format using bcl2fastq v2.20.0.422. Read quality was assessed with FastQC. Adaptor trimming was performed using the Trim Reads v3.0 tool in CLC Genomics Workbench v24.0.1

(Qiagen), with default parameters except that 1 bp at the 3' end was removed; reads < 36 bp were discarded. Trimmed reads were mapped to the *Mus musculus* GRCm39 reference genome (Ensembl release 110) using strand-specific (reverse) settings (similarity fraction 0.8; length fraction 0.8). Gene expression levels were quantified as transcripts per million (TPM). Differential expression analysis was performed in R v4.5.1 using Welch's t-test ($p < 0.05$). Genes with $|\log_2 \text{fold change}| \geq 0.58$ were defined as differentially expressed. The top 30 differentially expressed genes, ranked by descending $\log_2$ fold change, were functionally annotated using UniProt. Annotation categories were ordered according to the number of assigned genes, and genes within each category were ranked by fold change. Venn diagrams were constructed to visualize upregulated and downregulated genes in Mcont compared with Ycont and McKO groups.

Single-cell RNA-seq data analysis

Publicly available single-cell RNA sequencing data (GSE145477)²⁵ were reanalyzed using R v4.4.1 and the Seurat package v4.3.0. Cells expressing fewer than 100 detected genes or more than 30% mitochondrial transcripts were excluded. Genes detected in fewer than three cells were removed. Remaining cells were normalized and scaled using the standard Seurat workflow. Highly variable genes (2,000 per dataset) were identified with the "vst" method. Principal component analysis (PCA) was performed, and datasets were integrated using reciprocal PCA (RPCA)-based anchoring (FindIntegrationAnchors and IntegrateData). Dimensionality reduction and clustering were performed using RunUMAP, FindNeighbors, and FindClusters. Clustering resolutions of 0.1 and 0.05 were used for Fig. 4d and Extended Data Fig. 5a, respectively. Endothelial cells with detectable *Tnfrsf11a* expression in the raw count matrix (count > 0) were defined as RANK⁺ endothelial cells, whereas cells with no detectable *Tnfrsf11a* expression (count = 0) were defined as RANK⁻ endothelial cells. Differentially expressed genes were identified using the FindMarkers function in Seurat with the Wilcoxon rank-sum test. Genes with $p < 0.05$ and $|\log_2 \text{fold change}| \geq 0.58$ were considered significant. Volcano plots were generated using ggplot2 and ggrepel. Gene set enrichment analysis (GSEA) was performed in Metascape (<http://metascape.org>) using the top 600 differentially expressed genes (ranked by $\log_2$ fold change), evaluating enrichment for Gene Ontology Biological Processes, KEGG pathways, and Reactome gene sets.

Cell cultures and cell staining

ST2 cells (RIKEN) were cultured in α -MEM supplemented with 10% FBS, L-glutamine, and antibiotic-antimycotic at 37 °C under 5% CO₂. Cells were treated with recombinant mouse IL-1 β (R&D Systems; 5 ng/ml) for 10 days for senescence assays, which were assessed by SA- β -gal staining (KAA002RF; Millipore) and γ H2AX immunostaining using an anti-phospho-Histone H2A.X antibody (clone 20E3; Cell Signaling Technology; 1:200). For osteogenic differentiation, ST2 cells were cultured in osteogenic medium consisting of 100 μ g/mL L-ascorbic acid, 10 mM β -glycerophosphate, and 100 ng/ml recombinant human BMP2 (355-BEC-010; R&D Systems), with or without IL-1 β . ALP staining was performed using a TRAP/ALP staining kit according to the manufacturer's instructions. HUVECs

(C2519A; Lonza) were maintained in EGM-2 medium (CC-3162; Lonza). Cells were transiently transfected with a TNFRSF11A (RANK) expression plasmid or control EGFP vector (VectorBuilder) using the Cytofect™-HUVEC Transfection Kit (TF200K; Cell Applications) according to the manufacturer's instructions. After 24 h, the medium was replaced with EBM-2, and cells were stimulated with recombinant soluble RANKL (100 ng/mL) for 24 h. Total RNA was extracted using TRIzol reagent for quantitative RT-PCR analysis. Mitochondrial membrane potential was assessed using the JC-1 MitoMP Detection Kit (MT09; Dojindo) according to the manufacturer's instructions. ST2 cells were treated with IL-1 β (5 ng/mL) for 24 h and stained with JC-1 for 1 h at 37 °C. Images were acquired using a Keyence fluorescence microscope. $\Delta\Psi_m$ was quantified in ImageJ as the background-corrected red/green fluorescence intensity ratio on a per-cell basis (50 cells per experiment, $n = 3$). ST2 cells were treated with IL-1 β (5 ng/ml) for 10 min. Intracellular reactive oxygen species (ROS) levels were measured using the ROS Assay Kit -Photo-oxidation Resistant DCFH-DA- (R253; Dojindo) according to the manufacturer's instructions, with staining performed for 30 min.

Western blotting

ST2 cells were treated with IL-1 β (5 ng/ml) for 10 days and lysed in RIPA buffer supplemented with protease and phosphatase inhibitors. Lysates were resolved by 10% SDS-PAGE and transferred to PVDF membranes using a semi-dry system. Membranes were blocked in 5% BSA in TBS-Tween (TBST) for 1 h at room temperature and incubated overnight at 4 °C with primary antibodies against CDKN2A/p16^{INK4a} (clone EPR20418, Abcam, 1:1000), p21 (clone EPR18021; Abcam; 1:1000) and β -actin (8H10D10; Cell Signaling Technology; 1:5000). After washing, membranes were incubated for 1 h at room temperature with HRP-conjugated anti-rabbit secondary antibodies (NA934; Cytiva; 1:10000) for p16 and p21, and HRP-conjugated anti-mouse secondary antibodies (NA931; Cytiva; 1:50000) for β -actin. Signals were detected by enhanced chemiluminescence. Protein levels were normalized to β -actin and expressed relative to untreated controls.

Reanalysis of public RNA-seq data

Public RNA-seq count data (GSE141610) were downloaded from the Gene Expression Omnibus (GEO). Differential gene expression analysis was performed using the DESeq2 package. Genes were ranked according to the Wald statistic from the denosumab versus placebo comparison. Pre-ranked gene set enrichment analysis (GSEA) was performed using the GSEA function implemented in the clusterProfiler package. Gene sets were obtained from the Molecular Signatures Database (MSigDB) using the msigdb package, including Hallmark (H), curated (C2), and Gene Ontology Biological Process (C5) collections. Gene sets containing 5–500 genes were included in the analysis, and multiple testing correction was performed using the Benjamini–Hochberg method.

Quantification and statistical analysis

Statistical analyses were performed using GraphPad Prism 9 (GraphPad Software). Data are presented as mean $\pm$ s.d., and sample sizes are indicated in the corresponding figure legends. Two-group

comparisons were conducted using unpaired two-tailed Welch's t-tests. For multiple-group comparisons, Brown–Forsythe and Welch ANOVA were performed, followed by Dunnett's T3 multiple comparisons test. ImageJ was used to quantify RANKL⁺ and ALP⁺ areas, and fluorescence intensities were analyzed using ZEN 3.2 (Zeiss). A P value < 0.05 was considered statistically significant. RNA-seq and scRNA-seq analyses are described separately.

Declarations

Competing interests

The authors declare no competing interests.

Materials & Correspondence

Correspondence and requests for materials should be addressed to Yasuhiro Kobayashi (yasuhiro.kobayashi@mdu.ac.jp).

Funding

This work was supported by JSPS KAKENHI grants 22K17008 (R.I.), 25K12979 (R.I.), 24H00653 (Y.K.), 22K18402 (Y.K.), and 24K02629 (N.U.) from the Ministry of Education, Culture, Sports, Science and Technology of Japan, and by grants from The Naito Foundation and the Terumo Life Science Foundation (Y.K.).

Author contributions

Y.K. initiated and supervised the project and wrote the manuscript. R.I. performed most of the experiments, analyzed data, prepared figures, and wrote the manuscript. T.T., M.I., Z.H., K.M., T.H. (Toru Hiraga), and H.Y. (Hisataka Yasuda) contributed to experiments and data analysis. T.H. (Tomoyo Hara), B.G., H.Y. (Hiroki Yamagami), and I.E. interpretation of the RANKL-neutralizing antibody experiment results. T.I., Y.A., and M.T. reanalyzed the scRNA-seq database. T.M. provided methodological support. M.N. and N.U. provided critical reagents and experimental animals. K.O., H.T., and N.U. contributed to study design and data interpretation. All authors reviewed and approved the final manuscript.

Acknowledgements

We thank the members of the Institute for Oral Science and the Department of Histology and Cell Biology, Matsumoto Dental University, for valuable discussions and technical assistance. We also thank

the Department of Genomics & Proteomics, Advanced Science Research Center, Okayama University, for technical support in RNA-seq analysis, and the Research Center for Supports to Advanced Science, Shinshu University, for support with confocal microscopy and flow cytometric cell sorting.

Data availability

The bulk RNA-seq data generated in this study will be deposited in the Gene Expression Omnibus (GEO) and will be publicly available upon publication. Publicly available scRNA-seq data analyzed in this study were obtained from GEO under accession number GSE145477.

Code availability

Scripts used for data analysis are available from the corresponding author upon reasonable request.

References

1. Palmer, A. K. et al. Cellular senescence: at the nexus between aging and diabetes. *Diabetologia* 62, 1835-1841 (2019). DOI: 10.1007/s00125-019-4934-x
2. Khosla, S. et al. The role of cellular senescence in aging and endocrine disease. *Nat. Rev. Endocrinol* 16, 263-275 (2020). DOI: 10.1038/s41574-020-0335-y
3. Ding Y. et al. Comprehensive human proteome profiles across a 50-year lifespan reveal aging trajectories and signatures. *Cell* 188, 5763-5784.e26 (2025). DOI: 10.1016/j.cell.2025.06.047.
4. Zhang, Q. et al. Senescent cells: an emerging target for diseases of aging. *Nat Rev Drug Discov* 16, 718-735 (2017). DOI: 10.1038/nrd.2017.116
5. Gasek, N. S. et al. Strategies for targeting senescent cells in human disease. *Nat Aging* 1, 870-879 (2021). DOI: 10.1038/s43587-021-00121-8
6. Rodier, F. et al. Persistent DNA damage signaling triggers senescence-associated inflammatory cytokine secretion. *Nat. Cell Biol.* 11, 973-979 (2009). DOI: 10.1038/ncb1909
7. Herranz, N. & Gil J. Mechanisms and functions of cellular senescence. *J Clin Invest.* 128, 1238-1246 (2018). DOI: 10.1172/JCI95148
8. Sogabe, Y. et al. Characterizing primary and secondary senescence in vivo. *Nat Aging* 5, 1568-1588 (2025). DOI: 10.1038/s43587-025-00917-y
9. Franceschi, C. et al. Inflammaging and 'garb-aging'. *Trends Endocrinol Metab* 28, 199-212 (2017). DOI: 10.1016/j.tem.2016.09.005
10. Farr, J. et al. Targeting cellular senescence prevents age-related bone loss in mice. *Nat Med* 23, 1072-1079 (2017). DOI: 10.1038/nm.4385
11. Chaib, S. et al. Cellular senescence and senolytics: the path to the clinic. *Nat Med* 28, 1556-1568 (2022). DOI: 10.1038/s41591-022-01923-y

12. Ono T. et al. RANKL biology: bone metabolism, the immune system, and beyond. *Inflamm Regen* 40, 2 (2020). DOI: 10.1186/s41232-019-0111-3
13. Rao, S. et al. RANKL and RANK: From Mammalian Physiology to Cancer Treatment. *Trends Cell Biol* 28, 213-223 (2018). DOI: 10.1016/j.tcb.2017.11.001
14. Caiado, F. et al. IL-1 in aging and pathologies of hematopoietic stem cells. *Blood* 144, 368-377 (2024). DOI: 10.1182/blood.2023023105
15. Mitchell, C. A. et al. Stromal niche inflammation mediated by IL-1 signaling is a targetable driver of haematopoietic ageing. *Nat Cell Biol* 25, 30-41 (2023). DOI: 10.1038/s41556-022-01053-0
16. Frisch, B. J. et al. Aged marrow macrophages expand platelet-biased hematopoietic stem cells via Interleukin1B. *JCI Insight* 5, e124213 (2019). DOI: 10.1172/jci.insight.124213
17. Bucay, N. et al. osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. *Genes Dev* 12, 1260-8 (1998). DOI: 10.1101/gad.12.9.1260
18. Kim, Y. H. et al. Mid-old cells are a potential target for anti-aging interventions in the elderly. *Nat Commun* 14, 7619 (2023). DOI: 10.1038/s41467-023-43491-w
19. Young, K. et al. Decline in IGF1 in the bone marrow microenvironment initiates hematopoietic stem cell aging. *Cell Stem Cell* 28, 1473-1482.e7 (2021). DOI: 10.1016/j.stem.2021.03.017
20. Ho, Y. H. et al. Remodeling of bone marrow hematopoietic stem cell niches promotes myeloid cell expansion during premature or physiological aging. *Cell Stem Cell* 25, 407-418.e6 (2019). DOI: 10.1016/j.stem.2019.06.007
21. Elias, H. K. et al. Molecular mechanisms underlying lineage bias in aging hematopoiesis. *Semin Hematol* 54, 4-11 (2017). DOI: 10.1053/j.seminhematol.2016.11.002
22. Pang, W. W. et al. Human bone marrow hematopoietic stem cells are increased in frequency and myeloid-biased with age. *Proc Natl Acad Sci U S A* 108, 20012-7 (2011). DOI: 10.1073/pnas.1116110108
23. Mizoguchi T. et al. Identification of cell cycle-arrested quiescent osteoclast precursors in vivo. *J Cell Biol* 184, 541-554 (2009). DOI: 10.1083/jcb.200806139
24. Gibon, E. et al. Inflammation, aging, and bone regeneration. *J Orthop Translat* 10, 28-35 (2017). DOI: 10.1016/j.jot.2017.04.002
25. Zhong, L. et al. Single cell transcriptomics identifies a unique adipose lineage cell population that regulates bone marrow environment. *Elife* 9, e54695 (2020). DOI: 10.7554/eLife.54695
26. Weivoda, M. M. et al. Identification of osteoclast-osteoblast coupling factors in humans reveals links between bone and energy metabolism. *Nat. Commun.* 11, 87 (2020). Doi: 10.1038/s41467-019-14003-6
27. Kusumbe, A. et al. Coupling of angiogenesis and osteogenesis by a specific vessel subtype in bone. *Nature* 507, 323-328 (2014). DOI: 10.1038/nature13145
28. Langen, U. et al. Cell-matrix signals specify bone endothelial cells during developmental osteogenesis. *Nat Cell Biol* 19, 189-201 (2017). DOI: 10.1038/ncb3476

29. Kaneko, T. et al. The RANK/RANKL axis controls vascular dynamics in the bone marrow. *Proc. Natl Acad. Sci. USA* 122, e2425366122 (2025). DOI: 10.1073/pnas.2425366122
30. Khosla, S. et al. Correlates of osteoprotegerin levels in women and men. *Osteoporos. Int.* **13**, 394–399 (2002). DOI: 10.1007/s001980200045
31. Kudlacek, S. et al. Serum levels of osteoprotegerin increase with age in a healthy adult population. *Bone* **32**, 681–686 (2003). DOI: 10.1016/S8756-3282(03)00129-1
32. Tsukasaki, M. et al. OPG Production Matters Where It Happened. *Cell Rep.* 2020;32(10):108124. DOI:10.1016/j.celrep.2020.108124
33. Jin, S. et al. Interleukin-34 restores blood-brain barrier integrity by upregulating tight junction proteins in endothelial cells. *PLoS ONE* 9, e115981 (2014). DOI: 10.1371/journal.pone.0115981
34. Miyamoto, T. et al. Bifurcation of osteoclasts and dendritic cells from common progenitors. *Blood* 98, 2544-2554 (2001). DOI: 10.1182/blood.V98.8.2544
35. Maeda, K. et al. Wn5a-Ror2 signaling between osteoblast-lineage cells and osteoclast precursors enhances osteoclastogenesis. *Nat Med* 18, 405-412 (2012). DOI: 10.1038/nm.2653
36. Aarreberg, L. D. et al. Interleukin-1 β Induces mtDNA Release to Activate Innate Immune Signaling via cGAS-STING. *Mol Cell* 74, 801-815.e6. (2019). DOI: 10.1016/j.molcel.2019.02.038
37. Dinarello, C. A. Biologic basis for interleukin-1 in disease. *Blood* 87, 2095-2147 (1996). DOI: 10.1182/blood.V87.6.2095.bloodjournal8762095
38. Dixit, V & Mak, T. W. NF-kappaB signaling. Many roads lead to madrid. *Cell* 111, 615-619 (2002). DOI: 10.1016/s0092-8674(02)01166-2
39. Boyce, B. F. & Xing, L. Functions of RANKL/RANK/OPG in bone modeling and remodeling. *Arch Biochem Biophys* 473, 39-146 (2008). DOI: 10.1016/j.abb.2008.03.018
40. Ock, S. et al. Receptor activator of nuclear factor- κ B ligand is a novel inducer of myocardial inflammation. *Cardiovasc Res* 94, 105-114 (2012). DOI: 10.1093/cvr/cvs078
41. Hou, J. et al. Aged bone marrow macrophages drive systemic aging and age-related dysfunction via extracellular vesicle-mediated induction of paracrine senescence. *Nat Aging* 4, 1562-1581 (2024). DOI: 10.1038/s43587-024-00694-0
42. Mizuno, A. et al. Severe osteoporosis in mice lacking osteoclastogenesis inhibitory factor/osteoprotegerin. *Biochem. Biophys. Res. Commun.* 247, 610-615 (1998). DOI: 10.1006/bbrc.1998.8697
43. Kogata, N. et al. Cardiac ischemia activates vascular endothelial cadherin promoter in both preexisting vascular cells and bone marrow cells involved in neovascularization. *Circ. Res.* 98, 897-904 (2006). DOI: 10.1161/01.RES.0000218193.51136.ad
44. Powell, J. J. et al. An endogenous nanomineral chaperones luminal antigen and peptidoglycan to intestinal immune cells. *Nat. Nanotechnol.* 10, 361-9 (2015). DOI: 10.1038/nnano.2015.19
45. Madisen, L. et al. A robust and high-throughput Cre reporting and characterization system for the whole mouse brain. *Nat. Neurosci.* 13, 133-40 (2010). DOI: 10.1038/nn.2467

46. Furuya, Y. et al. Increased bone mass in mice after single injection of anti-receptor activator of nuclear factor-kappaB ligand-neutralizing antibody: evidence for bone anabolic effect of parathyroid hormone in mice with few osteoclasts. *J. Biol. Chem.* 286, 37023-37031 (2011). DOI: 10.1074/jbc.M111.246280
47. Buxsein, M. L. et al. Guidelines for assessment of bone microstructure in rodents using micro-computed tomography. *J. Bone Miner. Res.* 25, 1468-1486 (2010). DOI: 10.1002/jbmr.141
48. Parfitt, A. M. et al. Bone histomorphometry: Standardization of nomenclature, symbols, and units. *J. Bone Miner. Res.* 2, 595-610 (1987). DOI: 10.1002/jbmr.5650020617
49. Kawakami, M. et al. Development of a method for the identification of receptor activator of nuclear factor- κ B⁺ populations in vivo. *J. Oral Biosci.* 63, 45–51 (2021). DOI: 10.1016/j.job.2021.01.009
50. Matsushita, Y. et al. A Wnt-mediated transformation of the bone marrow stromal cell identity orchestrates skeletal regeneration. *Nat. Commun.* 11, 332 (2020). DOI: 10.1038/s41467-019-14029-w

Figures




Figure 1

OPG deficiency accelerates age-associated bone phenotypes. a, SPiDER- β -gal activity in femora from young and middle-aged WT and OPG KO mice. $n = 5$ biological replicates. Scale bar, 50 μ m. **b**, Flow cytometric analysis of Ly6G⁺CD11b⁺ neutrophils and CD3⁺ or B220⁺ lymphocytes within the CD45⁺ bone marrow cell population from young and middle-aged WT and OPG KO mice. $n = 5$ biological replicates. **c**, Quantitative RT-PCR analysis of senescence markers and SASP genes in tibiae from young and middle-aged WT and middle-aged OPG KO mice. $n = 4$ biological replicates. **d**, SPiDER- β -gal activity in bone marrow from young OPG KO mice treated with anti-RANKL antibody or control IgG. $n = 3$ biological replicates. Scale bar, 50 μ m. **e**, Immunofluorescence of Ly6G⁺ neutrophils and CD3⁺ or B220⁺ lymphocytes in bone marrow from young OPG KO mice treated with anti-RANKL antibody or control IgG. $n = 3$ biological replicates. Scale bar, 50 μ m. **f**, μ CT analysis of trabecular bone parameters in femora from young OPG KO mice treated with anti-RANKL antibody or control IgG. $n = 3$ biological replicates. Scale bar, 1 mm. **a–f**, Data are presented as mean $\pm$ s.d. Statistical significance was determined using Brown–Forsythe and Welch ANOVA followed by Dunnett’s T3 multiple-comparisons test or unpaired two-tailed Welch’s t -test (* $P < 0.05$, ** $P < 0.01$, *** $P < 0.001$, **** $P < 0.0001$).




Figure 1

OPG deficiency accelerates age-associated bone phenotypes. a, SPiDER- β -gal activity in femora from young and middle-aged WT and OPG KO mice. $n = 5$ biological replicates. Scale bar, 50 μ m. **b,** Flow cytometric analysis of Ly6G⁺CD11b⁺ neutrophils and CD3⁺ or B220⁺ lymphocytes within the CD45⁺ bone marrow cell population from young and middle-aged WT and OPG KO mice. $n = 5$ biological replicates.

c, Quantitative RT-PCR analysis of senescence markers and SASP genes in tibiae from young and middle-aged WT and middle-aged OPG KO mice. $n = 4$ biological replicates. **d,** SPiDER- β -gal activity in bone marrow from young OPG KO mice treated with anti-RANKL antibody or control IgG. $n = 3$ biological replicates. Scale bar, 50 μ m. **e,** Immunofluorescence of Ly6G⁺ neutrophils and CD3⁺ or B220⁺ lymphocytes in bone marrow from young OPG KO mice treated with anti-RANKL antibody or control IgG. $n = 3$ biological replicates. Scale bar, 50 μ m. **f,** μ CT analysis of trabecular bone parameters in femora from young OPG KO mice treated with anti-RANKL antibody or control IgG. $n = 3$ biological replicates. Scale bar, 1 mm. **a–f,** Data are presented as mean $\pm$ s.d. Statistical significance was determined using Brown–Forsythe and Welch ANOVA followed by Dunnett’s T3 multiple-comparisons test or unpaired two-tailed Welch’s t -test (* $P < 0.05$, ** $P < 0.01$, *** $P < 0.001$, **** $P < 0.0001$).




Figure 2

RANK⁺ endothelial cells are increased in middle-aged bone marrow

a, Immunofluorescence of CD31 and Emcn in femora from middle-aged control and EC-RANK cKO mice after intravenous injection of Fluor555-rRANKL. *n* = 3 biological replicates. Scale bar, 50 μ m. **b**, Flow cytometric analysis of Fluor555-rRANKL binding to endothelial (CD31⁺CD45⁻), stromal (CD31⁻CD45⁻), and immune (CD31⁻CD45⁺) cells populations in bone marrow from middle-aged WT mice. Gray histograms indicate unstained controls, and pink histograms indicate Fluor555-rRANKL staining.

c, RANK immunofluorescence in femora from young and middle-aged VE-cadherin-tom mice. $n = 5$ biological replicates. Scale bar, 50 μm . **d**, CD31 and Emcn immunofluorescence in femora from young and middle-aged RANK-tom mice. $n = 5$ biological replicates. Scale bar, 50 μm . **a,c,d**, Data are presented as mean $\pm$ s.d. Statistical significance was determined using unpaired two-tailed Welch's t -test (* $P < 0.05$, ** $P < 0.01$, *** $P < 0.001$, **** $P < 0.0001$). **b**, Data are presented as median with interquartile range. Statistical significance was determined using the Kruskal–Wallis test ($P < 0.0001$).




Figure 3

Endothelial RANK promotes age-associated bone phenotypes

a, μ CT analysis of trabecular bone parameters in femora from young and middle-aged control (RANK^{fl/fl}) and middle-aged EC-RANK cKO (VE-cadherin-Cre; RANK^{fl/fl}) mice. $n = 6$ biological replicates. Scale bar, 1 mm. **b**, p16 immunofluorescence in femora from young and middle-aged control and EC-RANK cKO mice. $n = 6$ biological replicates. Scale bar, 50 μ m. **c**, Flow cytometric analysis of Ly6G⁺CD11b⁺ neutrophils and CD3⁺ or B220⁺ lymphocytes within the CD45⁺ bone marrow cell population from young and middle-aged control and EC-RANK cKO mice. $n = 5$ biological replicates. **d,e**, Immunofluorescence of Ly6G⁺ neutrophils (**d**) and CD3⁺ or B220⁺ lymphocytes (**e**) in bone marrow 2 weeks after 5-FU treatment in young and middle-aged control and EC-RANK cKO mice. $n = 6$ biological replicates. Scale bars, 50 μ m. **f**, μ CT analysis of trabecular bone parameters in femora after bone marrow ablation from middle-aged control and EC-RANK cKO mice. $n = 6$ biological replicates. Scale bar, 1 mm. **g**, Osterix immunofluorescence in femora after bone marrow ablation from middle-aged control and EC-RANK cKO mice. $n = 6$ biological replicates. Scale bar, 50 μ m. **a–g**, Data are presented as mean $\pm$ s.d. Statistical significance was determined using Brown–Forsythe and Welch ANOVA followed by Dunnett’s T3 multiple-comparisons test or unpaired two-tailed Welch’s t -test (* $P < 0.05$, ** $P < 0.01$, *** $P < 0.001$, **** $P < 0.0001$).




Figure 3

Endothelial RANK promotes age-associated bone phenotypes

a, μ CT analysis of trabecular bone parameters in femora from young and middle-aged control (*RANK^{fl/fl}*) and middle-aged EC-RANK cKO (*VE-cadherin-Cre; RANK^{fl/fl}*) mice. $n = 6$ biological replicates. Scale bar, 1 mm. **b**, p16 immunofluorescence in femora from young and middle-aged control and EC-RANK cKO mice. $n = 6$ biological replicates. Scale bar, 50 μ m. **c**, Flow cytometric analysis of Ly6G⁺CD11b⁺

neutrophils and CD3⁺ or B220⁺ lymphocytes within the CD45⁺ bone marrow cell population from young and middle-aged control and EC-RANK cKO mice. *n* = 5 biological replicates. **d,e**, Immunofluorescence of Ly6G⁺ neutrophils (**d**) and CD3⁺ or B220⁺ lymphocytes (**e**) in bone marrow 2 weeks after 5-FU treatment in young and middle-aged control and EC-RANK cKO mice. *n* = 6 biological replicates. Scale bars, 50 μ m. **f**, μ CT analysis of trabecular bone parameters in femora after bone marrow ablation from middle-aged control and EC-RANK cKO mice. *n* = 6 biological replicates. Scale bar, 1 mm. **g**, Osterix immunofluorescence in femora after bone marrow ablation from middle-aged control and EC-RANK cKO mice. *n* = 6 biological replicates. Scale bar, 50 μ m. **a–g**, Data are presented as mean $\pm$ s.d. Statistical significance was determined using Brown–Forsythe and Welch ANOVA followed by Dunnett’s T3 multiple-comparisons test or unpaired two-tailed Welch’s *t*-test (**P* < 0.05, ***P* < 0.01, ****P* < 0.001, *****P* < 0.0001).




Figure 4

Aged endothelial cells express IL-1 β in a RANK-dependent manner

a, Bulk RNA-seq analysis of femora from young control (Ycont), middle-aged control (Mcont), and middle-aged EC-RANK cKO (McKO) mice. Heatmap of secreted genes differentially expressed in Mcont compared with Ycont. $n = 3$ biological replicates. **b**, Heatmap of secreted genes differentially expressed

between Mcont and McKO mice. $n = 3$ biological replicates. **c**, Venn diagrams of differentially expressed genes (DEGs; Welch's t -test, $P < 0.05$, $|\log_2FC| \geq 0.58$). Numbers indicate DEG counts and shared genes. $n = 3$ biological replicates. **d**, TPM values of genes commonly upregulated or downregulated in Mcont compared with Ycont and McKO mice. $n = 3$ biological replicates. **e**, Endothelial cells with detectable *Tnfrsf11a* transcripts in the raw count matrix (count > 0) were defined as RANK⁺ endothelial cells, whereas cells with no detectable *Tnfrsf11a* transcripts (count = 0) were defined as RANK⁻ endothelial cells.

f, Quantitative RT-PCR analysis of *Il1b* expression in endothelial cells (CD31⁺CD45⁻Ter119⁻) isolated from tibiae and femora of young and middle-aged WT mice. $n = 3$ biological replicates. **g**, IL-1 β immunofluorescence in femora from young and middle-aged VE-cadherin-tom mice. $n = 6$ biological replicates. Scale bar, 50 μ m. **h**, IL-1 β immunofluorescence in femora from young and middle-aged control and EC-RANK cKO mice. $n = 6$ biological replicates. Scale bar, 50 μ m. **d,f-h**, Data are presented as mean $\pm$ s.d. Statistical significance was determined using Brown-Forsythe and Welch ANOVA followed by Dunnett's T3 multiple-comparisons test or unpaired two-tailed Welch's t -test (* $P < 0.05$, **** $P < 0.0001$).




Figure 5

Neutralization of IL-1 β ameliorates age-associated bone phenotypes

a,b, Feature **(a)** and violin **(b)** plots of *Il1r1* expression in bone marrow cells and BMSCs (cluster 0) at 1.5 and 16 months using scRNA-seq data (GSE145477). Statistical significance was determined using a two-sided Wilcoxon rank-sum test. **c**, γ H2AX immunofluorescence in ST2 cells treated with vehicle or IL-

1 β (5 ng/mL) for 10 days. n = 3 biological replicates. **d**, SA- β -gal staining in ST2 cells treated with vehicle or IL-1 β (5 ng/mL) for 10 days. n = 3 biological replicates. **e**, LepR immunofluorescence and SPiDER- β -gal staining in femora from middle-aged WT mice treated with anti-IL-1 β antibody or control IgG. n = 6 biological replicates. Scale bar, 50 μ m. **f**, Flow cytometric analysis of Ly6G⁺CD11b⁺ neutrophils and CD3⁺ or B220⁺ lymphocytes within the CD45⁺ bone marrow cell population from middle-aged mice treated with anti-IL-1 β antibody or control IgG. n = 6 biological replicates.

g, μ CT analysis of trabecular bone parameters in femora after bone marrow ablation from middle-aged WT mice treated with anti-IL-1 β antibody or control IgG. n = 5 biological replicates. Scale bar, 1 mm. **h**, Osterix immunofluorescence in femora after bone marrow ablation from middle-aged WT mice treated with anti-IL-1 β antibody or control IgG. n = 6 biological replicates. Scale bar, 50 μ m. **c–h**, Data are presented as mean $\pm$ s.d. Statistical significance was determined using unpaired two-tailed Welch's t -test (* P < 0.05, ** P < 0.01).




Figure 6

RANKL antibody ameliorates age-associated phenotypes in mice and humans

a, SPiDER- β -gal staining in bone marrow from middle-aged WT mice treated with anti-RANKL antibody or control IgG. $n = 6$ biological replicates. Scale bar, 50 μ m. **b**, Flow cytometric analysis of Ly6G⁺CD11b⁺ neutrophils and CD3⁺ or B220⁺ lymphocytes within the CD45⁺ bone marrow cell population from middle-aged mice treated with anti-RANKL antibody or control IgG. $n = 6$ biological replicates.

c, Gene set enrichment analysis (GSEA) of representative pathways associated with IL-1 signaling (GOBP_RESPONSE_TO_INTERLEUKIN_1), inflammation (HALLMARK_INFLAMMATORY_RESPONSE), and senescence (SAUL_SEN_MAYO) in denosumab- and placebo-treated human bone biopsies. Positive normalized enrichment scores (NES) indicate enrichment in the placebo group, whereas negative NES indicate enrichment in the denosumab group. NES and false discovery rate (FDR)-adjusted P values are shown for each pathway.

d, Proposed model of endothelial RANK signaling in skeletal inflammaging. **a–c**, Data are presented as mean $\pm$ s.d. Statistical significance was determined using unpaired two-tailed Welch's t -test or paired two-tailed t -test (**P < 0.01, ***P < 0.001, ****P < 0.0001, ns, not significant).

Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- [IwamotoetalExtendedDataFigure.docx](#)